Table 2.
Number of individual published mentions of HAE-C1INH and AD comorbidity grouped by MedDRA v21.0 high level terms
| High level MedDRA term | Number of HAE comorbid AD mentions |
|---|---|
| Lupus erythematosus and associated conditions | 52 |
| Systemic lupus erythematosus | 30 |
| Lupus | 7 |
| Discoid lupus | 8 |
| Lupus-like disease | 4 |
| Cutaneous lupus | 2 |
| Drug-induced lupus | 1 |
| Endocrine autoimmune disorders | 21 |
| Thyroid diseases | 21 |
| Glomerulonephritis and nephrotic syndrome | 16 |
| Glomerulonephritis | 16 |
| Gastrointestinal inflammatory conditions | 16 |
| Crohn’s disease | 8 |
| Celiac disease | 7 |
| Ulcerative colitis | 1 |
| Rheumatoid arthritis and associated conditions | 11 |
| Rheumatoid arthritis | 11 |
| Eye, salivary gland and connective tissue disorders | 10 |
| Sjogren’s syndrome | 7 |
| Sicca syndrome | 1 |
| Mixed connective tissue disease | 2 |
| Immune and associated conditions not elsewhere classified | 5 |
| Psoriasis | 3 |
| Psoriatic arthritis | 2 |
Groups with ≥ 5 mentions are shown
AD autoimmune disease, C1-INH C1 esterase inhibitor, HAE hereditary angioedema, MedDRA Medical Dictionary for Regulatory Activities